About Oxford BioMedica (LON:OXB)
Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company's segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners. The R&D segment is engaged in the development of in-vivo and ex-vivo gene and cell therapy products, and the development of lentivirus-related platform technology. The Company provides a platform of technologies and capabilities with which it designs, develops and produces gene and cell-based medicines. The Company's product pipeline of OXB-102, OXB-201, OXB-202 and OXB-302 addresses neurodegenerative and ocular diseases, and a range of cancers. OXB-102 is indicated for Parkinson's disease. OXB-202 is indicated for Ocular (corneal graft rejection). OXB-302 is indicated for cancer disease. Its OXB-201 is indicated for wet age-related macular degeneration.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-56.98%
Return on Assets-11.53%
Oxford BioMedica (LON:OXB) Frequently Asked Questions
What is Oxford BioMedica's stock symbol?
Oxford BioMedica trades on the London Stock Exchange (LON) under the ticker symbol "OXB."
Where is Oxford BioMedica's stock going? Where will Oxford BioMedica's stock price be in 2018?
3 brokers have issued 12 month target prices for Oxford BioMedica's stock. Their forecasts range from GBX 10.20 to GBX 13. On average, they anticipate Oxford BioMedica's stock price to reach GBX 12.07 in the next twelve months. View Analyst Ratings for Oxford BioMedica.
Who are some of Oxford BioMedica's key competitors?
Some companies that are related to Oxford BioMedica include Insys Therapeutics (INSY), Five Prime Therapeutics (FPRX), Coherus Biosciences (CHRS), Rigel Pharmaceuticals (RIGL), ZIOPHARM Oncology (ZIOP), Synergy Pharmaceuticals (SGYP), Keryx Biopharmaceuticals (KERX), Urogen Pharma (URGN), Aduro BioTech (ADRO), Uniqure (QURE), BioCryst Pharmaceuticals (BCRX), Tyme Technologies (TYME), Kura Oncology (KURA), Clementia Pharmaceuticals (CMTA), Sorrento Therapeutics (SRNE), Cytokinetics (CYTK), Achaogen (AKAO) and Karyopharm Therapeutics (KPTI).
Who are Oxford BioMedica's key executives?
Oxford BioMedica's management team includes the folowing people:
- John Dawson, Chief Executive Officer, Executive Director (Age 56)
- Stuart Paynter, Chief Financial Officer, Director
- Peter Nolan, Executive Director, Chief Business Officer (Age 62)
- Lorenzo Tallarigo M.D., Non-Executive Chairman of the Board (Age 64)
- Andrew John William Heath M.D., Ph.D., Non-Executive Deputy Chairman of the Board, Senior Independent Director (Age 69)
- Martin Diggle, Non-Executive Director (Age 52)
- Stuart Henderson, Non-Executive Director
How do I buy Oxford BioMedica stock?
Shares of Oxford BioMedica and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Oxford BioMedica's stock price today?
One share of Oxford BioMedica stock can currently be purchased for approximately GBX 10.40.
How big of a company is Oxford BioMedica?
Oxford BioMedica has a market capitalization of £323.20 million.
How can I contact Oxford BioMedica?
Oxford BioMedica's mailing address is Windrush Court, Transport Way, OXFORD, OX4 6LT, United Kingdom. The biopharmaceutical company can be reached via phone at +44-1865-783000.
MarketBeat Community Rating for Oxford BioMedica (OXB)MarketBeat's community ratings are surveys of what our community members think about Oxford BioMedica and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Oxford BioMedica (LON:OXB)
No earnings announcements for this company have been tracked by MarketBeat.com
Oxford BioMedica (LON:OXB) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Oxford BioMedica (LON:OXB)
No dividend announcements for this company have been tracked by MarketBeat.com
Oxford BioMedica (LON OXB) Insider Trading and Institutional Ownership History
Oxford BioMedica (LON OXB) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/20/2017||Lorenzo Tallarigo||Insider||Buy||29,365||GBX 9||£2,642.85|
|11/23/2017||Lorenzo Tallarigo||Insider||Buy||30,861||GBX 9||£2,777.49|
|10/23/2017||Lorenzo Tallarigo||Insider||Buy||30,436||GBX 9||£2,739.24|
|9/26/2017||Andrew Heath||Insider||Buy||110,511||GBX 9||£9,945.99|
|9/22/2017||Lorenzo Tallarigo||Insider||Buy||29,685||GBX 9||£2,671.65|
|9/15/2017||Martin Diggle||Insider||Buy||100,000||GBX 8||£8,000|
|9/1/2017||Martin Diggle||Insider||Buy||320,000||GBX 9||£28,800|
|8/31/2017||Martin Diggle||Insider||Sell||2,377,600||GBX 10||£237,760|
|7/17/2017||Peter Nolan||Insider||Buy||249,687||GBX 8||£19,974.96|
|7/13/2017||Martin Diggle||Insider||Buy||660,000||GBX 9||£59,400|
|6/23/2017||Lorenzo Tallarigo||Insider||Buy||49,033||GBX 5||£2,451.65|
|5/24/2017||Lorenzo Tallarigo||Insider||Buy||53,260||GBX 5||£2,663|
|4/24/2017||Lorenzo Tallarigo||Insider||Buy||54,090||GBX 5||£2,704.50|
|3/23/2017||Lorenzo Tallarigo||Insider||Buy||49,468||GBX 5||£2,473.40|
|2/24/2017||Lorenzo Tallarigo||Insider||Buy||67,165||GBX 4||£2,686.60|
|12/15/2016||Lorenzo Tallarigo||Insider||Buy||65,993||GBX 4||£2,639.72|
|11/25/2016||Lorenzo Tallarigo||Insider||Buy||75,417||GBX 4||£3,016.68|
|10/25/2016||Lorenzo Tallarigo||Insider||Buy||77,864||GBX 3||£2,335.92|
|9/26/2016||Lorenzo Tallarigo||Insider||Buy||79,988||GBX 3||£2,399.64|
|8/25/2016||Tallarigo ,Lorenzo||Insider||Buy||62,257||GBX 4||£2,490.28|
|7/25/2016||Tallarigo ,Lorenzo||Insider||Buy||63,351||GBX 4||£2,534.04|
|6/24/2016||Tallarigo ,Lorenzo||Insider||Buy||62,847||GBX 4||£2,513.88|
|5/13/2016||Diggle ,Martin||Insider||Buy||42,072||GBX 5||£2,103.60|
|5/12/2016||Diggle ,Martin||Insider||Buy||45,428||GBX 5||£2,271.40|
|5/5/2016||Diggle ,Martin||Insider||Buy||12,500||GBX 6||£750|
|5/4/2016||Diggle ,Martin||Insider||Buy||44,689||GBX 6||£2,681.34|
|5/3/2016||Diggle ,Martin||Insider||Buy||317,382||GBX 6||£19,042.92|
|4/22/2016||Tallarigo ,Lorenzo||Insider||Buy||41,083||GBX 6||£2,464.98|
|3/24/2016||Tallarigo ,Lorenzo||Insider||Buy||41,550||GBX 6||£2,493|
|2/26/2016||Diggle ,Martin||Insider||Buy||29,345||GBX 7||£2,054.15|
|2/25/2016||Tallarigo ,Lorenzo||Insider||Buy||36,370||GBX 7||£2,545.90|
|2/24/2016||Diggle ,Martin||Insider||Buy||46,693||GBX 6||£2,801.58|
|7/1/2015||Diggle ,Martin||Insider||Buy||284,439||GBX 0.09||£256|
|6/30/2015||Diggle ,Martin||Insider||Buy||775,000||GBX 0.09||£697.50|
|6/19/2015||Diggle ,Martin||Insider||Buy||225,000||GBX 0.08||£180|
|6/12/2015||Martin Diggle||Insider||Buy||283,978||GBX 9.01||£25,586.42|
|6/11/2015||Martin Diggle||Insider||Buy||416,022||GBX 9||£37,441.98|
|6/9/2015||Daniel Soland||Insider||Buy||500,000||GBX 9.45||£47,250|
|5/21/2015||Andrew Heath||Insider||Buy||100,000||GBX 10.60||£10,600|
|5/19/2015||Tim Watts||Insider||Buy||194,174||GBX 10.30||£19,999.92|
Oxford BioMedica (LON OXB) News Headlines
|Lorenzo Tallarigo Acquires 29,365 Shares of Oxford BioMedica plc (OXB) Stock|
www.americanbankingnews.com - December 20 at 8:24 AM
|Primary analysis results from JULIET trial - London South East (blog)|
www.lse.co.uk - December 11 at 4:50 PM
|Lorenzo Tallarigo Acquires 30,861 Shares of Oxford BioMedica plc (OXB) Stock|
www.americanbankingnews.com - November 23 at 10:32 AM
|Is Oxford BioMedica PLC’s (LSE:OXB) Balance Sheet Strong Enough To Weather A Storm?|
finance.yahoo.com - November 10 at 9:33 AM
|OXB to present at Jefferies Healthcare Conference - London South East (blog)|
www.lse.co.uk - November 9 at 3:27 PM
|Oxford BioMedica notes the sBLA submission to FDA for Kymriah(TM) in adult patients with r/r DLBCL - GlobeNewswire (press release)|
globenewswire.com - November 1 at 7:23 AM
|Oxford BioMedica notes the sBLA submission to FDA for Kymriah(TM) in adult patients with r/r DLBCL|
feeds.benzinga.com - October 31 at 12:44 PM
|Oxford BioMedica plc (OXB) Insider Purchases £2,739.24 in Stock|
www.americanbankingnews.com - October 23 at 1:32 PM
|Andrew Heath Acquires 110,511 Shares of Oxford BioMedica plc (OXB) Stock|
www.americanbankingnews.com - September 26 at 1:28 PM
|Oxford BioMedica plc (OXB) Now Covered by Peel Hunt|
www.americanbankingnews.com - September 24 at 6:32 PM
|Lorenzo Tallarigo Buys 29,685 Shares of Oxford BioMedica plc (OXB) Stock|
www.americanbankingnews.com - September 22 at 10:27 AM
|Oxford BioMedica plc (OXB) Insider Martin Diggle Acquires 100,000 Shares|
www.americanbankingnews.com - September 15 at 10:27 AM
|Oxford BioMedica plc (OXB) Releases Earnings Results|
www.americanbankingnews.com - September 11 at 7:12 AM
|Oxford BioMedica plc (OXB) Insider Martin Diggle Sells 2,377,600 Shares|
www.americanbankingnews.com - September 5 at 10:34 AM
|Insider Buying: Oxford BioMedica plc (OXB) Insider Buys 320,000 Shares of Stock|
www.americanbankingnews.com - September 5 at 10:34 AM
|Oxford BioMedica plc (OXB) Scheduled to Post Earnings on Monday|
www.americanbankingnews.com - September 4 at 2:22 AM
|Oxford BioMedica plc (LON:OXB) Given New GBX 8.70 Price Target at N+1 Singer|
www.americanbankingnews.com - July 27 at 11:22 AM
|Peter Nolan Buys 249,687 Shares of Oxford BioMedica plc (LON:OXB) Stock|
www.americanbankingnews.com - July 17 at 11:29 AM
|Insider Buying: Oxford BioMedica plc (OXB) Insider Buys 660,000 Shares of Stock|
www.americanbankingnews.com - July 14 at 1:56 PM
|Oxford BioMedica plc's (LON:OXB) "Not Rated" Rating Reaffirmed at Shore Capital|
www.americanbankingnews.com - July 13 at 3:10 PM
|Oxford BioMedica plc (LON:OXB) Stock Rating Reaffirmed by N+1 Singer|
www.americanbankingnews.com - July 9 at 7:30 AM
|Investors Chronicle: Bellway, M&C Saatchi, Oxford Biomedica - Financial Times|
www.ft.com - March 25 at 8:51 AM
|[$$] Investors Chronicle: Bellway, M&C Saatchi, Oxford Biomedica|
www.ft.com - March 24 at 6:58 PM
|Oxford BioMedica's (OXBDF) CEO John Dawson on Q4 2016 Results - Earnings Call Transcript|
seekingalpha.com - March 17 at 12:52 AM
|UK STOCKS-Factors to watch on March 16|
www.reuters.com - March 16 at 8:44 AM
|Full Year 2016 Oxford BioMedica PLC Earnings Release - Before Market Open|
biz.yahoo.com - March 16 at 8:44 AM
|Director Dealings / Market Share Purchase - London South East (registration) (blog)|
www.lse.co.uk - January 25 at 5:56 AM
|Findings Reported by Novartis on CTL-019 at ASH - London South East (registration) (blog)|
www.lse.co.uk - December 5 at 7:03 PM
|Result of General Meeting and Directors Dealing - London South East (registration) (blog)|
www.lse.co.uk - September 30 at 6:43 PM
Oxford BioMedica (LON:OXB) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Oxford BioMedica (LON OXB) Stock Chart for Monday, January, 22, 2018